EP3104864 - METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 11.01.2019 Database last updated on 30.10.2024 | |
Former | Request for examination was made Status updated on 18.11.2016 | Most recent event Tooltip | 11.01.2019 | Application deemed to be withdrawn | published on 13.02.2019 [2019/07] | Applicant(s) | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris / FR | For all designated states Institut Pasteur De Lille 1 rue du Professeur Calmette 59000 Lille / FR | For all designated states Centre National de la Recherche Scientifique (C.N.R.S.) 3, rue Michel-Ange 75016 Paris / FR | For all designated states Université de Lille 1 Sciences et Technologies Cité Scientifique 59650 Villeneuve d'Ascq / FR | For all designated states Université de Droit et de la Santé de Lille 2 42, rue Paul Duez 59800 Lille / FR | [2016/51] | Inventor(s) | 01 /
GOSSET, Philippe Inserm U 1019 Institut Pasteur de Lille 1 Rue du Professeur Calmette BP245 F-59019 Lille Cedex / FR | 02 /
PICHAVANT, Muriel Inserm U 1019 Institut Pasteur de Lille 1 Rue du Professeur Calmette BP245 F-59019 Lille Cedex / FR | 03 /
REMY, Gaëlle Inserm U 1019 Institut Pasteur de Lille 1 Rue du Professeur Calmette BP245 F-59019 Lille Cedex / FR | [2016/51] | Representative(s) | Collin, Matthieu Inserm-Transfert Paris Biopark 7, rue Watt 75013 Paris / FR | [2016/51] | Application number, filing date | 15705274.7 | 13.02.2015 | [2016/51] | WO2015EP53041 | Priority number, date | EP20140305201 | 14.02.2014 Original published format: EP 14305201 | [2016/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015121393 | Date: | 20.08.2015 | Language: | EN | [2015/33] | Type: | A1 Application with search report | No.: | EP3104864 | Date: | 21.12.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.08.2015 takes the place of the publication of the European patent application. | [2016/51] | Search report(s) | International search report - published on: | EP | 20.08.2015 | Classification | IPC: | A61K31/7032, C07K16/28, A61K39/00 | [2016/51] | CPC: |
A61K31/7032 (EP,US);
A61K39/092 (US);
A61K39/102 (US);
A61K45/06 (US);
C07K16/2809 (EP,US);
A61K2039/505 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/51] | Title | German: | VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG AKUTER VERSCHLIMMERUNGEN DER CHRONISCH OBSTRUKTIVEN LUNGENERKRANKUNG | [2016/51] | English: | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | [2016/51] | French: | PROCÉDÉS ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT D'EXACERBATIONS AIGUËS DE LA MALADIE PULMONAIRE OBSTRUCTIVE CHRONIQUE | [2016/51] | Entry into regional phase | 06.07.2016 | National basic fee paid | 06.07.2016 | Designation fee(s) paid | 06.07.2016 | Examination fee paid | Examination procedure | 06.07.2016 | Amendment by applicant (claims and/or description) | 06.07.2016 | Examination requested [2016/51] | 06.07.2016 | Date on which the examining division has become responsible | 01.09.2018 | Application deemed to be withdrawn, date of legal effect [2019/07] | 04.10.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2019/07] | Fees paid | Renewal fee | 23.02.2017 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 28.02.2018 | 04   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2011149881 (CHILDRENS MEDICAL CENTER [US], et al) [X] 1 * claims 19, 20 * * page 31, paragraph 110 * * page 75, paragraph 263 * * page 22, paragraph 64; figures 7A-7G * [I] 1-18; | [XDI]WO2013063395 (NKT THERAPEUTICS INC [US]) [XD] 1,6 * claims 1, 2, 7, 38; sequences 28, 29 * [I] 1,6-14; | [I] - SHIRONJIT SAHA ET AL, "Eosinophilic airway inflammation in COPD", INTERNATIONAL JOURNAL OF COPD, (20060101), vol. 1, pages 39 - 47, XP055113673 [I] 1-18 * the whole document * | [Y] - KAWAKAMI KAZUYOSHI ET AL, "Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (20031201), vol. 33, no. 12, doi:10.1002/EJI.200324254, ISSN 0014-2980, pages 3322 - 3330, XP002455359 [Y] 1-18 * abstract * DOI: http://dx.doi.org/10.1002/eji.200324254 | [Y] - YUKO MORISHIMA ET AL, "Suppression of eosinophilic airway inflammation by treatment with [alpha]-galactosylceramide", EUROPEAN JOURNAL OF IMMUNOLOGY, (20051001), vol. 35, no. 10, doi:10.1002/eji.200525994, ISSN 0014-2980, pages 2803 - 2814, XP055111416 [Y] 1-18 * the whole document * DOI: http://dx.doi.org/10.1002/eji.200525994 | [A] - DAVID DOMBROWICZ, "Exploiting the innate immune system to control allergic asthma", EUROPEAN JOURNAL OF IMMUNOLOGY, (20051001), vol. 35, no. 10, doi:10.1002/eji.200535425, ISSN 0014-2980, pages 2786 - 2788, XP055111415 [A] 1-18 DOI: http://dx.doi.org/10.1002/eji.200535425 | [A] - Patricia Hachem ET AL, "Frontline: a-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: Role of IFN-c", (20051001), URL: http://onlinelibrary.wiley.com/store/10.1002/eji.200535268/asset/2793_ftp.pdf?v=1&t=hp0vseqw&s=36da291c1be3959fec09595bbfc51c3d22bb1e77, (20131210), XP055092438 [A] 1-18 * abstract * |